MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
|02/24/15||MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results|
|- Conference Call to Begin Today at 5:00 PM ET -
VALENCIA, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2014.
For the fourth quarter, our operating expenses declined 35% compared to the similar quarter in 2013. Research and development costs were significantly lower, mainly due to a reduction in non-cash compensation expenses and much lower clinical trial expenses followi... |
|02/18/15||MannKind Corporation to Present at the RBC Capital Markets Global Healthcare Conference|
|VALENCIA, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 2015 RBC Capital Markets Global Healthcare Conference on Wednesday, February 25, 2015 at 9:00 AM (ET) at the New York Palace in New York City.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company'... |
|02/17/15||MannKind Corporation to Hold 2014 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2015|
|VALENCIA, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on February 24, 2015.
Presenting from the Company will be its Chief Executive Officer, Hakan Edstrom and Chief Financial Officer, Matthew Pfeffe... |
|02/03/15||Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.|
|PARIS and VALENCIA, Calif., Feb. 3, 2015 /PRNewswire/ -- Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type 1 and type 2 diabetes.
Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7412351-sanofi-ma... |
|Data provided by Nasdaq. Minimum 15 minutes delayed.|